Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syncona Shs GBP ( (GB:SYNC) ) has shared an update.
Syncona has committed $24.5 million to Beacon Therapeutics’ oversubscribed $75 million Series C financing, boosting the valuation of its holding in the ophthalmic gene therapy company and lifting the carrying value of the stake by £29.3 million, a 20% uplift since September 2025. The new funding round, led by Goldman Sachs Alternatives with participation from the Retinal Degeneration Fund and existing investors, will support completion and commercial preparation of Beacon’s lead gene therapy laru-zova for X-linked retinitis pigmentosa, as well as advance its broader retinal disease pipeline; on full drawdown, Syncona’s holding in Beacon will be valued at about $237.6 million with a 38.4% ownership stake, underscoring the strategic importance of Beacon in Syncona’s portfolio ahead of pivotal clinical data expected in the second half of 2026.
The most recent analyst rating on (GB:SYNC) stock is a Hold with a £96.00 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.
Spark’s Take on GB:SYNC Stock
According to Spark, TipRanks’ AI Analyst, GB:SYNC is a Neutral.
The score is held back primarily by highly volatile and recently weak financial performance and negative technical momentum. Offsetting this are a conservatively positioned balance sheet (no debt) and positive corporate actions aimed at returning capital and improving shareholder value, but losses (negative P/E) keep the overall risk/quality profile mid-range.
To see Spark’s full report on GB:SYNC stock, click here.
More about Syncona Shs GBP
Syncona Limited is a UK-listed life sciences investment company that builds and invests in healthcare businesses, with a particular focus on innovative therapeutics. Its portfolio includes Beacon Therapeutics, an ophthalmic gene therapy specialist developing treatments for blinding retinal diseases such as X-linked retinitis pigmentosa and geographic atrophy.
Average Trading Volume: 488,653
Technical Sentiment Signal: Sell
See more insights into SYNC stock on TipRanks’ Stock Analysis page.